45.15

1.01% 0.45

After Hours: 45.15

Apogee Therapeutics Inc (APGE)

Overview News Price History Financials Discussions Forecast

Apogee Therapeutics Inc stock is traded at $45.15, with a volume of 203.67K. It is up +1.01% in the last 24 hours and down -19.85% over the past month. Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.

Previous Close:

$44.70

Open:

$44.74

24h Volume:

203.67K

Relative Volume:

0.49

Market Cap:

$2.57B

Revenue:

Net Income/Loss:

$-118.49M

P/E Ratio:

EPS:

Net Cash Flow:

$-110.57M

1W Performance:

+3.89%

1M Performance:

-19.85%

6M Performance:

-0.07%

1Y Performance:

+152.66%

1-Day Range:

$44.09

$45.73

1-Week Range:

$42.52

$45.99

52-Week Range:

$17.17

$72.29

Apogee Therapeutics Inc Stock (APGE) Company Profile

Name

Apogee Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

650-394-5230

Address

221 CRESCENT ST., WALTHAM

Employee

Twitter

Next Earnings Date

Latest SEC Filings

APGE's Discussions on Twitter

Compare APGE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APGE Apogee Therapeutics Inc	45.15	2.57B	0	-118.49M	-110.57M	-2.4041
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-25-24	Initiated	Canaccord Genuity	Buy
May-10-24	Initiated	BofA Securities	Buy
Dec-20-23	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	Guggenheim	Buy
Aug-08-23	Initiated	Jefferies	Buy
Aug-08-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Wedbush	Outperform

View All

Apogee Therapeutics Inc Stock (APGE) Latest News

09:45 AM

Braidwell LP Sells 748,816 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

09:45 AM

Nov 29, 2024

Apogee Therapeutics Announces Agenda for Virtual R&D Day - Marketscreener.com

Nov 29, 2024

Apogee Therapeutics Sets R&D Day to Unveil APG808 Clinical Trial Results, Pipeline Updates | APGE Stock News - StockTitan

Nov 29, 2024

Vestal Point Capital LP Acquires Shares of 136,500 Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Nov 29, 2024

Guggenheim lifts Apogee Therapeutics shares target on strategy By Investing.com - Investing.com Australia

Nov 29, 2024

Nov 28, 2024

Long Term Trading Analysis for (APGE) - Stock Traders Daily

Nov 28, 2024

Natixis Advisors LLC Invests $879,000 in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Nov 28, 2024

Nov 27, 2024

Guggenheim lifts Apogee Therapeutics shares target on strategy - Investing.com

Nov 27, 2024

Guggenheim Issues Positive Forecast for Apogee Therapeutics (NASDAQ:APGE) Stock Price - MarketBeat

Nov 27, 2024

Apogee Therapeutics price target raised to $110 from $95 at Guggenheim - TipRanks

Nov 27, 2024

Nov 26, 2024

Apogee Therapeutics (NASDAQ:APGE) Now Covered by Canaccord Genuity Group - Defense World

Nov 26, 2024

Nov 25, 2024

Interesting APGE Put And Call Options For December 2025 - Nasdaq

Nov 25, 2024

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga

Nov 25, 2024

Apogee Therapeutics (NASDAQ:APGE) Now Covered by Analysts at Canaccord Genuity Group - MarketBeat

Nov 25, 2024

Apogee Therapeutics (NASDAQ:APGE) Coverage Initiated by Analysts at Canaccord Genuity Group - MarketBeat

Nov 25, 2024

Apogee initiated with a Buy at Canaccord on APG777 ‘blockbuster potential’ - TipRanks

Nov 25, 2024

Apogee Therapeutics initiated with a Buy at Canaccord - TipRanks

Nov 25, 2024

Nov 19, 2024

Victory Capital Management Inc. Grows Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Nov 19, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Nov 19, 2024

Nov 18, 2024

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - Marketscreener.com

Nov 18, 2024

Apogee Therapeutics Unveils First R&D Day: Spotlight on APG777 and Immunology Pipeline | APGE Stock News - StockTitan

Nov 18, 2024

Nov 15, 2024

Wedbush Cuts Earnings Estimates for Apogee Therapeutics - MarketBeat

Nov 15, 2024

Nov 14, 2024

Driehaus Capital Management LLC Acquires Shares in Apogee Therap - GuruFocus.com

Nov 14, 2024

Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Nov 14, 2024

Stifel maintains Buy on Apogee Therapeutics with $95 target By Investing.com - Investing.com Australia

Nov 14, 2024

Nov 13, 2024

Stifel maintains Buy on Apogee Therapeutics with $95 target - Investing.com India

Nov 13, 2024

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024

Nov 10, 2024

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis - Seeking Alpha

Nov 10, 2024

Nov 09, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 6,665 Shares - MarketBeat

Nov 09, 2024

Michael Thomas Henderson Sells 15,000 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat

Nov 09, 2024